drugset / Trial / NCT02118714

Atrasentan Spermatogenesis and Testicular Function

NCT02118714

Phase 2 Completed 20 enrolled AbbVie
NaSingle-groupOpen-labelOther

Summary

This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy. This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).

Timeline

Start
2015-04-06
Primary completion
2018-04-18
Completion
2018-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Atrasentan Other / unclassified 0.75 mg Oral